Glaxo to co-promote Shire’s Vyvanse drug in US
* U.S. co-promotion will double Vyvanse sales effort * Three-year profit sharing deal targets adults with ADHD * Shire shares jump 7.2 percent (Adds analyst comment, shares) LONDON, March 31 (Reuters) - Shire (SHP.L) has struck a dealwith GlaxoSmithKline (GSK.L), the world's second largest drugsgroup, to co-promote its hyperactivity medicine Vyvanse in theUnited States , sending its shares sharply higher. Shire, Glaxo Enter Vyvanse Co-Promotion Agreement US called ill equipped f
Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with Adhd, Adults With Adhd, Glaxo, Glaxosmithkline, Gsk, Hyperactivity, London March, Medicine, Promotion Agreement, Reuters, Sales Effort, Shares, Shire, Shp, Targets, Theunited States, Vyvanse
